Literature DB >> 15673661

The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain.

M Riyaz Basha1, Wei Wei, Saleh A Bakheet, Nathalie Benitez, Hasan K Siddiqi, Yuan-Wen Ge, Debomoy K Lahiri, Nasser H Zawia.   

Abstract

The fetal basis of adult disease (FeBAD) hypothesis states that many adult diseases have a fetal origin. According to FeBAD, injury or environmental influences occurring at critical periods of organ development could result in "programmatic" changes via alterations in gene expression or gene imprinting that may result in functional deficits that become apparent later in life. Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by excessive deposits of aggregated beta-amyloid (Abeta) peptides, which are snippets of the beta-amyloid precursor protein (APP). The predominantly sporadic nature of AD suggests that the environment must play a role in neurodegeneration. To examine latent responses to an environmental agent, we exposed rodents to lead and monitored the lifetime expression of the APP gene. We observed that APP mRNA expression was transiently induced in neonates, but exhibited a delayed overexpression 20 months after exposure to Pb had ceased. This upregulation in APP mRNA expression was commensurate with a rise in activity of the transcription factor Sp1, one of the regulators of the APP gene. Furthermore, the increase in APP gene expression in old age was accompanied by an elevation in APP and its amyloidogenic Abeta product. In contrast, APP expression, Sp1 activity, as well as APP and Abeta protein levels were unresponsive to Pb exposure during old age. These data suggested that environmental influences occurring during brain development predetermined the expression and regulation of APP later in life, potentially altering the course of amyloidogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673661      PMCID: PMC6725614          DOI: 10.1523/JNEUROSCI.4335-04.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  32 in total

1.  Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome.

Authors:  A Nunomura; G Perry; K Hirai; G Aliev; A Takeda; S Chiba; M A Smith
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 2.  Metabolic programming in animals.

Authors:  S E Ozanne
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

3.  Cell death induced by a caspase-cleaved transmembrane fragment of the Alzheimer amyloid precursor protein.

Authors:  I Nishimura; T Uetsuki; K Kuwako; T Hara; T Kawakami; S Aimoto; K Yoshikawa
Journal:  Cell Death Differ       Date:  2002-02       Impact factor: 15.828

Review 4.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

5.  Lead-induced developmental perturbations in hippocampal Sp1 DNA-binding are prevented by zinc supplementation: in vivo evidence for Pb and Zn competition.

Authors:  Md Riyaz Basha; Wei Wei; Michelle Brydie; M Razmiafshari; N H Zawia
Journal:  Int J Dev Neurosci       Date:  2003-02       Impact factor: 2.457

Review 6.  A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease.

Authors:  Debomoy K Lahiri; Martin R Farlow; Kumar Sambamurti; Nigel H Greig; Ezio Giacobini; Lon S Schneider
Journal:  Curr Drug Targets       Date:  2003-02       Impact factor: 3.465

7.  Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain.

Authors:  M Morishima-Kawashima; N Oshima; H Ogata; H Yamaguchi; M Yoshimura; S Sugihara; Y Ihara
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

8.  Enhancer function and novel DNA binding protein activity in the near upstream betaAPP gene promoter.

Authors:  H W Querfurth; J Jiang; W Xia; D J Selkoe
Journal:  Gene       Date:  1999-05-17       Impact factor: 3.688

9.  Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype.

Authors:  Mona Thiruchelvam; Eric K Richfield; Becky M Goodman; Raymond B Baggs; Deborah A Cory-Slechta
Journal:  Neurotoxicology       Date:  2002-10       Impact factor: 4.294

Review 10.  Fetal programming of coronary heart disease.

Authors:  David J P Barker
Journal:  Trends Endocrinol Metab       Date:  2002-11       Impact factor: 12.015

View more
  105 in total

Review 1.  Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities.

Authors:  Lena Smirnova; Helena T Hogberg; Marcel Leist; Thomas Hartung
Journal:  ALTEX       Date:  2014       Impact factor: 6.043

2.  Altered clearance of beta-amyloid from the cerebrospinal fluid following subchronic lead exposure in rats: Roles of RAGE and LRP1 in the choroid plexus.

Authors:  Xiaoli Shen; Li Xia; Luqing Liu; Hong Jiang; Jonathan Shannahan; Yansheng Du; Wei Zheng
Journal:  J Trace Elem Med Biol       Date:  2020-04-08       Impact factor: 3.849

Review 3.  Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics.

Authors:  Kelly M Bakulski; Laura S Rozek; Dana C Dolinoy; Henry L Paulson; Howard Hu
Journal:  Curr Alzheimer Res       Date:  2012-06       Impact factor: 3.498

4.  Genome-wide expression and methylation profiling in the aged rodent brain due to early-life Pb exposure and its relevance to aging.

Authors:  Remi Dosunmu; Hany Alashwal; Nasser H Zawia
Journal:  Mech Ageing Dev       Date:  2012-05-18       Impact factor: 5.432

5.  Histone acetylation maps in aged mice developmentally exposed to lead: epigenetic drift and Alzheimer-related genes.

Authors:  Aseel Eid; Syed Waseem Bihaqi; Christopher Hemme; John M Gaspar; Ronald P Hart; Nasser H Zawia
Journal:  Epigenomics       Date:  2018-05-03       Impact factor: 4.778

Review 6.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

Review 7.  Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model.

Authors:  Debomoy K Lahiri; Nasser H Zawia; Nigel H Greig; Kumar Sambamurti; Bryan Maloney
Journal:  Biogerontology       Date:  2008-07-31       Impact factor: 4.277

8.  Gene × environment interaction by a longitudinal epigenome-wide association study (LEWAS) overcomes limitations of genome-wide association study (GWAS).

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Epigenomics       Date:  2012-12       Impact factor: 4.778

Review 9.  Epigenetics of early-life lead exposure and effects on brain development.

Authors:  Marie-Claude Senut; Pablo Cingolani; Arko Sen; Adele Kruger; Asra Shaik; Helmut Hirsch; Steven T Suhr; Douglas Ruden
Journal:  Epigenomics       Date:  2012-12       Impact factor: 4.778

10.  Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.

Authors:  Lina Adwan; Gehad M Subaiea; Nasser H Zawia
Journal:  Neuropharmacology       Date:  2014-01-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.